Optiver Holding
NYMX

Optiver Holding’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Optiver Holding’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,109
Closed -$13K – 924
2021
Q4 		$13K Hold
6,109
– – ﹤0.01% 667
2021
Q3 		$13K Hold
6,109
– – ﹤0.01% 535
2021
Q2 		$10K Buy
+6,109
New +$11.3K ﹤0.01% 457

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.7B AUM 31.52% 1-Year Est. Return
DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Optiver Holding's NYMX Position: Q1 2022 in Review

Optiver Holding sold out of Nymox Pharmaceutical Corp (NYMX) in Q1 2022, closing a stake of 6,109 shares — an estimated $13K sold.

Optiver Holding first reported a position in NYMX in Q2 2021 and held it in 3 quarters. The position peaked at $13K in Q4 2021. 40 funds tracked by Wall St. Rank hold NYMX as of Q1 2022.

  • Optiver Holding reported no remaining Nymox Pharmaceutical Corp position as of Q1 2022 after selling out during the quarter.
  • Optiver Holding sold 6,109 Nymox Pharmaceutical Corp shares in Q1 2022, an estimated $13K.
  • Optiver Holding first reported a position in Nymox Pharmaceutical Corp in Q2 2021 and held it in 3 quarters.
  • Optiver Holding's Nymox Pharmaceutical Corp position peaked at $13K in Q4 2021.
  • 40 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q1 2022.

Based on Optiver Holding's 13F filing for Q1 2022, filed 16 May 2022.